CMS Publishes Updated MLN Article on Allogeneic HSCT National Coverage Determination

The Centers for Medicare and Medicaid Services (CMS) recently published a Medicare Learning Network (MLN) article related to the national coverage determination (NCD) for allogeneic hematopoietic stem cell transplantation (HSCT) for patients with certain high-risk myelodysplastic syndromes (MDS). The NCD implementation date is Oct. 7.

On March 6, CMS issued a national coverage analysis  that expanded coverage of allogeneic HSCT using bone marrow, peripheral blood or umbilical cord blood stem cell products for Medicare patients with MDS who are categorized as intermediate-2, high-risk, or very high-risk for developing acute myeloid leukemia, as assessed by designated risk stratification systems.

AABB invites members to review the Association’s March 13 summary for additional information.